AC
IOVA icon

AXQ Capital’s Iovance Biotherapeutics IOVA Stock Holding History

AXQ Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$262K Buy
62,915
+14,046
+29% +$53.4K 0.03% 651
2026
Q1 		$172K Buy
+48,869
New +$156K 0.02% 787
2025
Q3 		– Sell
-56,404
Closed -$97K – 703
2025
Q2 		$97K Buy
56,404
+110
+0.2% +$274 0.03% 520
2025
Q1 		$187K Buy
+56,294
New +$290K 0.08% 404
2024
Q1 		– Sell
-17,400
Closed -$141K – 760
2023
Q4 		$141K Sell
17,400
-4,300
-20% -$22.5K 0.04% 578
2023
Q3 		$98.7K Buy
+21,700
New +$142K 0.03% 431

Other funds holding IOVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

AXQ Capital's IOVA Position: Q2 2026 in Review

AXQ Capital increased its Iovance Biotherapeutics (IOVA) stake by 29% in Q2 2026, buying an estimated $53.4K and bringing the position to 62,915 shares worth $262K. The position accounts for 0.03% of the portfolio, ranked #651.

AXQ Capital first reported a position in IOVA in Q3 2023 and has held it in 6 quarters since. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

  • AXQ Capital held 62,915 shares of Iovance Biotherapeutics worth $262K as of Q2 2026.
  • AXQ Capital bought 14,046 Iovance Biotherapeutics shares in Q2 2026, an estimated $53.4K.
  • Iovance Biotherapeutics made up 0.03% of AXQ Capital's portfolio in Q2 2026, its #651 holding.
  • AXQ Capital first reported a position in Iovance Biotherapeutics in Q3 2023 and has held it in 6 quarters since.
  • 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.